April 21, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
March 23, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy. New approach uses siRNA to silence NR2F6 activity in human immune cells.
February 24, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint InhibitorCompany is Currently Preparing IND for New Cancer Immuno-Therapy Drug
February 17, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc.’s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18
February 3, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
January 26, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
January 20, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
December 15, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy in Treatment of Aplastic Anemia.
December 1, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Attracts Top Researchers to Scientific Advisory Board.
December 1, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Attracts Top Researchers to Scientific Advisory Board.